The effects of macrophage activation on the outcome of allogeneic hematopoietic SCT (allo-HSCT) have yet to be fully examined. A total of 70 adult patients who received a first allo-HSCT for hematological diseases were studied. We counted the number of hemophagocytic cells in BM clot sections on day þ 14±7, and analyzed its impact on subsequent outcome. In all, 23 patients were diagnosed as having increased numbers of hemophagocytic cells (HP group), whereas 47 were not (non-HP group). The HP group was not associated with an increased incidence of acute or chronic GVHD, but was associated with worse hematopoietic recovery than the non-HP group. The 2-year OS for the HP group and the non-HP group was 30 and 65% (Po0.01), respectively, and 2-year nonrelapse mortality was 48% and 27% (Po0.01), respectively. Multivariate analysis confirmed that the HP group was associated with a lower OS (hazard ratio (HR) ¼ 2.3; 95% confidence interval (CI), 1.0-5.4; P ¼ 0.048) and higher non-relapse mortality (HR ¼ 4.0; 95% CI, 1.6-9.9; Po0.01). The HP group had higher incidences of death due to graft failure (Po0.01) and endothelial complications, such as sinusoidal obstruction syndrome and transplant-associated microangiopathy (P ¼ 0.01). Macrophage activation is a previously unrecognized complication with negative impact on outcome of allo-HSCT.
Introduction
Macrophages have an indispensable role in both innate and acquired immunity and they have at least 3 major functions: antigen presentation, phagocytosis and immunomodulation. 1, 2 Following allogeneic hematopoietic SCT (allo-HSCT), macrophages contribute to the development of acute GVHD by producing pro-inflammatory cytokines. 3 In addition to aGVHD, pro-inflammatory cytokine release is implicated in the pathogenesis of various early complications after allo-HSCT, such as sinusoidal obstruction syndrome, engraftment syndrome (ES) and capillary leakage syndrome. [4] [5] [6] [7] Although the role of macrophages in these complications is undetermined, macrophages have an ability to secrete significant amounts of pro-inflammatory cytokines. 2 Furthermore, fatal outcomes of hemophagocytic syndrome after allo-HSCT have been described in case reports. 8 This evidence suggests that activation of macrophages has a significant impact on post-transplantation outcome. However, there are only a few clinical studies that have analyzed the effects of macrophage activation on outcome of allo-HSCT. 9 Measuring the levels of cytokines or chemokines produced by activated macrophages, such as IL-1, IL-6, IL-12, TNF-a and macrophage inflammatory protein-1, may be a possible method to evaluate the activation of macrophages. 1, 2, 10 However, as these cytokines and chemokines are produced by many cell types, their elevated levels are not specific to macrophage activation. 1, [10] [11] [12] An alternative method for evaluating the activation of macrophages is to assess the morphological change associated with macrophage activation, namely phagocytosis. Although phagocytosis reflects only a part of macrophage activation, the increased number of phagocytic cells provides direct evidence that macrophages are activated. 2 In addition, assessment of hemophagocytosis can be carried out easily using BM clot sections. Thus, hemophagocytosis serves as a specific and simple marker of macrophage activation. We assessed hemophagocytosis in BM clot sections during the early post-transplantation period, and analyzed its impact on subsequent outcome.
Patients and methods

Patients
We reviewed 96 consecutive adult patients who received their first allo-BM or PBSCT between December 2005 and December 2008 at the Japanese Red Cross Nagoya First Hospital. As our purpose was to examine the impact of hemophagocytosis in BM clot sections on day þ 14±7 on subsequent outcome, two patients who died within the first 21 days after transplantation were excluded. Although BM aspiration is routinely performed on day þ 14±7 in our institution, it was not performed in 17 patients. In addition, specimens were insufficient for evaluation in seven patients. As a result, 70 patients were included in the analysis, all of whom received T cell-replete grafts. Standard risk diseases were defined as AML in first or second CR, ALL in first CR, CML in first chronic phase, myelodysplastic syndrome as refractory anemia, malignant lymphoma in CR, chronic active EB-virus infection, aplastic anemia and paroxysmal nocturnal hemoglobinuria, whereas high-risk diseases were defined as the others. This study was approved by the institutional review board. All patients provided written informed consent.
Transplantation procedure
Conditioning included myeloablative and reduced-intensity regimens. The myeloablative regimens were mainly CY/ TBI based, whereas the reduced-intensity conditioning regimens were mainly fludarabine 125 mg/m 2 plus melphalan 135-180 mg/m 2 . Antithymocyte globulin was added in two patients who received HLA-mismatched transplants, and alemtuzumab was added in one patient with aplastic anemia. For GVHD prophylaxis, CYA and short-term MTX were used for allo-HSCT from a related donor, and tacrolimus and short-term MTX for allo-HSCT from an unrelated donor. All patients were cared for in laminar airflow units and received oral gut decontamination. Standard prophylaxis against Pneumocystis carinii, fungal infections and herpes simplex virus was given. G-CSF was administered after transplantation in all patients until engraftment was confirmed. Engraftment was defined as an ANC of more than 500/mL for 3 consecutive days. Primary graft failure was said to have occurred when engraftment was not seen in patients surviving more than 21 days after transplantation. 13 Secondary graft failure was defined as loss of neutrophil engraftment as determined by an ANC of less than 500/mL for 3 consecutive days after having achieved neutrophil engraftment, and no evidence of disease progression in the marrow.
14 ES was diagnosed, if patients presented with two or more of the following symptoms within 96 h of the start of neutrophil recovery (ANC 4100/mL): (1) fever (temperature 4 ¼ 38.51C) without an identifiable infectious cause; (2) weight gain 4 ¼ 5% over the pre-transplantation baseline weight; (3) erythematous rash not attributable to a medication; and (4) hypoxia, pulmonary infiltrates or both not attributable to infection or cardiac disease. 15, 16 Acute GVHD was evaluated by established criteria. 17 Chronic GVHD was evaluated in patients who survived beyond day þ 100 without a relapse according to the traditional Seattle criteria. 18 BM examination BM aspiration was routinely performed on day þ 14 ± 7. All specimens were fixed in formalin solution, embedded in paraffin and stained with hematoxylin-eosin. BM clot sections were reviewed retrospectively and the total number of hemophagocytic cells in three fields at a 200-fold magnification was counted (Figure 1 ).
Statistical considerations
Chi-square, Fisher's exact and Mann-Whitney tests were used to compare clinical and patient characteristics. The probability of survival was calculated using the KaplanMeier method, and the differences between groups were compared using log-rank statistics. Probabilities of nonrelapse mortality (NRM) and relapse were calculated using the cumulative incidence function. 19 For NRM, relapse was the competing event, and for relapse, death in the absence of persistent or recurrent disease was the competing event. As our purpose was to examine the impact of hemophagocytosis in BM clot sections on day þ 14±7 on subsequent outcomes, all time-to-event comparisons were made from day þ 21 after transplantation. were entered into multivariable models and sequentially eliminated in a stepwise backward manner. Potential prognostic factors considered in the analysis were recipient age, disease risk, hematopoietic cell transplantation-specific comorbidity index, 20 HLA disparity in the GVH direction in HLA-A, -B, -C, -DRB1 alleles, donor type (related or unrelated), donor-recipient sex-match, conditioning regimen, SC source, GVHD prophylaxis, total number of hemophagocytic cells in BM clot sections on day þ 14 ± 7 and presence or absence of documented infections between day þ 7 and day þ 21. ES, sinusoidal obstruction syndrome, intestinal transplant-associated microangiopathy (intestinal TAM), 21, 22 and posterior reversible encephalopathy syndrome were categorized as endothelial complications, as they are caused by vascular endothelial damage. 4, 5, [21] [22] [23] [24] [25] P-values of less than 0.05 were considered statistically significant.
Results
Patient characteristics
The median age of patients was 43 (range, 17-61) years.
and paroxysmal nocturnal hemoglobinuria (n ¼ 2). Disease risk was standard in 40 patients and high in 30 patients. HLA was matched in the GVH direction in 47 patients, and matched in the host-vs-graft direction in 45 patients. Myeloablative conditioning regimens were used in 40 patients, and reduced-intensity conditioning regimens in 30. GVHD prophylaxis consisted of a combination of CYA and short-term MTX (n ¼ 21) or that of tacrolimus and short-term MTX (n ¼ 49). The median follow-up period of survivors was 556 (range, 236-1272) days.
The median total number of hemophagocytic cells in three fields was two (range, 0-30). The patients were divided into two groups on the basis of nearly bimodal distribution of total numbers of hemophagocytic cells ( Figure 2 ): HP group (total number of hemophagocytic cells 4 ¼ 5, median 8, n ¼ 23) and non-HP group (total number of hemophagocytic cells o5, median 1, n ¼ 47). Patient characteristics are summarized in Table 1 . There were no significant differences between the HP and non-HP groups.
Clinical and laboratory features
Clinical and laboratory features from day þ 7 to day þ 21 were compared between the HP and non-HP groups (Table 2) . Compared with the non-HP group, fever, neurological symptoms, body weight gain, hypoxia, elevated total bilirubin, elevated serum creatinine and elevated C-reactive protein were more frequent in the HP group. In contrast, there were no significant differences in the incidence of skin rash and diarrhea between the two groups.
Among the 23 patients in the HP group, 14 (61%) developed infections between day þ 7 and þ 21. The causes of these infections were bacteria (n ¼ 9), adenovirus and BK virus (n ¼ 1), CMV (n ¼ 1), human herpesvirus-6 (n ¼ 1), aspergillus (n ¼ 1) and bacteria and aspergillus (n ¼ 1). Of the 47 patients in the non-HP group, 8 (17%) developed infections. The causes of these infections were bacteria (n ¼ 5), adenovirus (n ¼ 2) and Pneumocystis carinii (n ¼ 1). The incidence of infections between day þ 7 and þ 21 was significantly higher in the HP group (Po0.01).
Hematopoietic recovery
Five patients (22%) in the HP group had graft failure, whereas one patient (2%) in the non-HP group had graft failure (P ¼ 0.01). Of these six patients, four had primary graft failure and two in the HP group had secondary graft failure. The median time to ANC 500/mL was 18 (range, 12-32) days in the HP group and 15 (range, 11-23) days in the non-HP group (Po0.01). Median time to platelet 50 000/mL was 31 (range, 18-214) days and 24.5 (range, 11-94) days, respectively (P ¼ 0.04), and the median time to reticulocyte 1% was 24.5 (range, 17-38) days and 20 (range, 13-38) days, respectively (Po0.01).
We next analyzed hematopoietic recovery after excluding 22 patients who had concomitant infections because the HP group included significantly more patients who had concomitant infections, and infections are known to interfere with effective and sustained reconstitution of hematopoiesis.
14 One (11%) out of nine patients in the HP group had graft failure, whereas one (3%) out of the 39 patients in the non-HP group had graft failure (P ¼ 0.34). The HP group was associated with significantly slower neutrophil, platelet and reticulocyte recovery than the non-HP group (18 days vs 14.5 days, Po0.01 for neutrophil recovery; 36 days vs 24 days, P ¼ 0.01 for platelet recovery; 24 days vs 19.5 days, P ¼ 0.02 for reticulocyte recovery). To eliminate the effect of PBSC use on hematopoietic recovery, we carried out subgroup analysis that included only those patients who received BMT. This subgroup analysis also showed that the HP group was associated with worse hematopoietic recovery than the non-HP group (data not shown).
Engraftment syndrome and GVHD Among those patients who engrafted, there was no significant difference in the incidence of ES between the OS, non-relapse mortality and relapse When patients were divided into quartiles according to the total number of hemophagocytic cells, 20 patients were in the first quartile (no hemophagocytic cells), 18 were in the second quartile (1 to 2 hemophagocytic cells), 19 were in the third quartile (3 to 7 hemophagocytic cells) and 13 were in the fourth quartile (8 or more hemophagocytic cells). As the cut-off point of 5 or more hemophagocytic cells was used to define the HP group, the third quartile was further divided into two groups (3 to 4 and 5 to 7 hemophagocytic cells). A 2-year cumulative incidences of NRM for patients with 0 to 4 hemophagocytic cells were 18-33%, whereas those for patients with 5 or more hemophagocytic cells were as high as approximately 50% (Table 3) .
OS rates for the HP group and non-HP group were 52 and 94% at day þ 100, and 30 and 65% at 2 years (Po0.01), respectively ( Figure 3 ). Cumulative incidences of NRM for the HP group and non-HP group were 43 and 4% at day þ 100, and 48 and 27% at 2 years (Po0.01), respectively ( Figure 4a ). The cumulative incidences of relapse for the HP group and non-HP group were 22 and 13% at 2 years (P ¼ 0.31), respectively (Figure 4b) .
Results of univariate and multivariate analysis of factors affecting post-transplantation outcomes are summarized in Table 4 . Multivariate analysis showed that the prognostic factors for lower OS were HP group (hazard ratio (HR) ¼ 2.3; 95% confidence interval (CI), 1.0-5.4; P ¼ 0.048), high-risk disease (HR ¼ 3.8; 95% CI, 1.6-9.1; Po0.01), and presence of infections (HR ¼ 3.2; 95% CI, 1.2-8.3; P ¼ 0.02). Similarly, the prognostic factors for higher NRM were HP group (HR ¼ 4.0; 95% CI, 1.6-9.9; Po0.01), and patient age 4 ¼ 50 years (HR ¼ 4.5; 95% CI, 1.7-12; Po0.01). Furthermore, HP group was associated with an increased NRM at day þ 100 on multivariate analysis (HR ¼ 11; 95% CI, 2.4-52; Po0.01). Multivariate analysis showed that the prognostic factors for higher relapse rates were HP group (HR ¼ 3.6; 95% CI, 1.1-12; P ¼ 0.04), and high-risk disease (HR ¼ 4.9; 95% CI, 1.0-23; P ¼ 0.047).
Causes of death
Of 23 patients in the HP group, 16 died. Their causes of death were relapse (n ¼ 5), graft failure (n ¼ 4), ES (n ¼ 1), posterior reversible encephalopathy syndrome (n ¼ 1), sinusoidal obstruction syndrome (n ¼ 1), intestinal TAM 21, 22 (n ¼ 2), and infection (n ¼ 2). Of 47 patients in the non-HP group, 14 died. Their causes of death were relapse (n ¼ 5), interstitial pneumonia (n ¼ 3), infection (n ¼ 2), cryptogenic organizing pneumonia (n ¼ 1), chronic GVHD (n ¼ 1), intestinal TAM (n ¼ 1), and secondary cancer (n ¼ 1). The incidence of death due to graft failure was significantly higher in the HP group than in the non-HP group (17 vs 0%, Po0.01), and that of death due to endothelial complications (ie, ES, sinusoidal obstruction syndrome, intestinal TAM, and posterior reversible encephalopathy syndrome) was significantly higher in the HP group than in the non-HP group (22 vs 2%, P ¼ 0.01).
Discussion
This study demonstrated that activation of macrophages in the BM early in the post-transplant period was associated Impact of hemophagocytosis on allo-HSCT N Imahashi et al with impaired hematopoietic recovery, distinctive clinical and laboratory features, higher NRM rates and lower OS rates. The results of this study revealed that early macrophage activation is an important complication, which has a significant impact on outcomes of allo-HSCT. In this study, 23 out of 70 patients (33%) were diagnosed as having hemophagocytosis. This suggests that early macrophage activation is a relatively common but unrecognized complication. Even if none of the 26 patients excluded from the analysis had hemophagocytosis, the incidence of hemophagocytosis would be still as high as 24% (23/96) .
Factors known to influence hematopoietic recovery after allo-HSCT include intensity of conditioning, cell dose and HLA compatibility.
14 Although there were no significant differences in these factors between the HP group and the non-HP group, the incidence of graft failure was higher and hematopoietic recovery was slower in the HP group than in the non-HP group. The HP group was associated with slower hematopoietic recovery than the non-HP group when excluding from analysis those patients who had concomitant infections, which are known to interfere with reconstitution of hematopoiesis.
14 Furthermore, among those patients who received BM as a SC source, the HP group had inferior hematopoietic recovery to the non-HP group. Thus, the HP group is an independent factor affecting hematopoietic recovery.
Analysis of clinical features demonstrated that fever, neurological symptoms, weight gain, hypoxia, elevated Abbreviations: AST ¼ aspartate aminotransferase; ALT ¼ alanine aminotransferase; CRP ¼ C-reactive protein; LDH ¼ lactate dehydrogenase. a Diarrhea, which is grade 3 or 4 according to the National Cancer Institute common toxicity criteria. b Body weight of one patient in the HP group and one patient in the non-HP group was not evaluable because of poor performance status.
Table 3
Non-relapse mortality and OS according to the total number of hemophagocytic cells than in the non-HP group (HP group: 52% at day þ 100 and 30% at 2 years; non-HP group: 94% at day þ 100 and 65% at 2 years; Po0.01). the HP group than in the non-HP group (HP group: 43% at day þ 100 and 48% at 2 years; non-HP group: 4% at day þ 100 and 27% at 2 years; Po0.01). (b) Cumulative incidences of relapse did not differ significantly between the HP group and the non-HP group (HP group: 22% at 2 years; non-HP group: 13% at 2 years; P ¼ 0.31).
Impact of hemophagocytosis on allo-HSCT N Imahashi et al total bilirubin and elevated serum creatinine were more frequently observed among the HP group than the non-HP group. These abnormalities are similar to those observed in ES. Furthermore, macrophage activation, ES and aGVHD share the common feature of being associated with elevated levels of pro-inflammatory cytokines.
2,3,5 Therefore, we speculated that there might be an overlap between early macrophage activation following allo-HSCT, ES and aGVHD, but there were no statistically significant differences in the incidence of ES and that of aGVHD between the HP group and the non-HP group. These results suggest that early macrophage activation was rather an independent complication from ES and aGVHD, although we could not draw a definite conclusion because of insufficient statistical power of this analysis.
The HP group had significantly higher NRM rates, resulting in significantly worse OS compared with the non-HP group. Although the incidence of concomitant infections was significantly higher in the HP group over the non-HP group, multivariate analysis demonstrated that the HP group and concomitant infections were independent risk factors for OS. Therefore, early macrophage activation seems to be an independent complication affecting transplant outcome. Of note, the incidence of death due to graft failure and endothelial complications was significantly higher in the HP group than in the non-HP group. Elevated levels of pro-inflammatory cytokines associated with activated macrophages such as TNF-a and macrophage inflammatory protein-1a might have contributed to the development of graft failure and exacerbation of endothelial complications, resulting in higher NRM rates in the HP group. 6, 7, 10, 26, 27 That C-reactive protein values were found to be higher in the HP group than in the non-HP group suggested that early macrophage activation was associated with a hyperinflammatory state. Future studies to measure the serum cytokine levels are warranted. The results of our study suggest that early identification of patients at high risk of NRM might be possible by simply performing BM aspiration on day þ 14 ± 7. This may have important implications for future therapeutic strategies because we could potentially lower the NRM rates by administering macrophage-targeted therapies in those patients who have an increased number of hemophagocytic cells in BM on day þ 14 ± 7. The potential therapeutic options targeting macrophages could include anti-TNFa agents, etoposide or liposomal corticosteroids. [28] [29] [30] [31] As we cannot rule out the possibility that early macrophage activation is the result rather than the cause of inflammatory processes, prospective trials are warranted to examine whether macrophage-targeted therapies for early macrophage activation can lower NRM rates.
Unexpectedly, the HP group was a risk factor for relapse in multivariate Cox regression analysis. However, this result should be interpreted with caution because of the relatively small sample size of our study. The impact of macrophage activation on relapse needs to be confirmed by larger studies.
Many types of cells decrease conspicuously in number following conditioning therapy, whereas macrophages do not. 32 Accordingly, the 'proportion' of hemophagocytic cells is likely to increase in hypocellular BM, but the 'absolute number' of hemophagocytic cells counted in BM clot sections would be little affected by the cellularity of BM. Additionally, it is difficult to distinguish between hemophagocytic cells and macrophages covered with other cells in BM smears, whereas overlapping of cells is virtually negligible in clot sections because clot sections are very thin (2 mm). For these reasons, we counted the absolute number of hemophagocytic cells in BM clot sections in this study.
We tested CD163 immunostaining in an effort to increase objectivity. CD163 is a specific marker for cells of the monocyte/macrophage lineage. 33 There was a good, but not perfect, correlation between the total number of CD163 þ macrophages and that of hemophagocytic cells identified by hematoxylin-eosin staining (Spearman r ¼ 0.70, Po0.01), which could be explained by the fact that hemophagocytic macrophages identified by hematoxylin-eosin staining are a sub-population of CD163 þ macrophages. [34] [35] [36] Although an increased number of CD163 þ macrophages was not a statistically significant factor for NRM (adjusted HR 2.1; 95% CI, 0.85-5.0; P ¼ 0.11), limited statistical power precluded us from excluding a clinically meaningful effect of it. Further studies are warranted.
In conclusion, the activation of macrophages in the BM early in the post-transplantation period is a relatively common but unrecognized complication with a negative impact on outcomes of allo-HSCT. The results of our study indicate the clinical usefulness of BM examination during the early post-transplantation period for the prediction of outcome.
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